<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819921</url>
  </required_header>
  <id_info>
    <org_study_id>WI209149</org_study_id>
    <nct_id>NCT02819921</nct_id>
  </id_info>
  <brief_title>Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen</brief_title>
  <official_title>Desvenlafaxine for the Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen: a Randomized, Double-blind, Placebo-controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Korea Cancer Center Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, placebo-controlled study of desvenlafaxine versus placebo. The
      purpose of this study is to determine if desvenlafaxine was effective in decreasing the
      frequency and severity of hot flashes in breast cancer patients taking tamoxifen.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 10, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Reduction rate of hot flashes symptom score</measure>
    <time_frame>From baseline to Week 5 (Intervention is started from Week 1)</time_frame>
    <description>Participants would complete self -report daily diary on which they record the number and severities (1 - 4 points) of hot flashes from baseline to week 5. Each symptom severities are multiplied by the numbers of symptoms to determine the daily hot flashes symptom score. The mean of daily hot flashes symptom score of one week is calculated and regared as a hot flashes symptom score for the week. The efficacy of Desvenlafaxine is assessed by comparing the reduction rate of weekly hot flashes symptom score (= hot flashes symptom score at week 5 - hot flashes symptom score at baseline / hot flashes symptom score of baseline) for each group.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical impression state and change</measure>
    <time_frame>Week 1, Week 2, Week 5</time_frame>
    <description>Clinical global impression (CGI) would be used to assess clinical impression state and change.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peripheral neuropathy</measure>
    <time_frame>Week 1, Week 2, Week 5</time_frame>
    <description>European Organization for Research and Treatment of Cancer - Quality of Life Questionnaire - Chemotherapy-Induced Peripheral Neuropathy(EORTC-QLQ-CIPN-20) would be used to assess peripheral neuropathy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Baseline, Week 2, Week 5</time_frame>
    <description>Patient health questionnaire (PHQ-9) would be used to assess mood status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Baseline, Week 2, Week 5</time_frame>
    <description>Generalized anxiety disorder-7 (GAD-7) would be used to assess anxiety.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manic or Hypomanic symptoms.</measure>
    <time_frame>Baseline, Week 2, Week 5</time_frame>
    <description>Mood disorder questionnaire (MDQ) would be used to assess manic or hypomanic symptoms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality</measure>
    <time_frame>Baseline, Week 2, Week 5</time_frame>
    <description>Pittsburgh sleep quality index (PSQI) would be used to assess sleep quality.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chonotype</measure>
    <time_frame>Baseline</time_frame>
    <description>Morningness-Eveningness questionnaire (MEQ) would be used to assess chronotype.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circadian misalignment</measure>
    <time_frame>Baseline, Week 2, Week 5</time_frame>
    <description>Munich Chronotype Questionnaire (MCTQ) would be used to assess circadian misalignment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Baseline, Week 2, Week 5</time_frame>
    <description>Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-fatigue) would be used to assess fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>Baseline, Week 2, Week 5</time_frame>
    <description>Functional Assessment of Cancer Therapy-Breast (FACT-B) would be used to assess quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beliefs about medicines</measure>
    <time_frame>Baseline</time_frame>
    <description>Beliefs about Medicines Questionnaire (BMQ) would be used to assess beliefs about medicines.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Illness perception</measure>
    <time_frame>Baseline</time_frame>
    <description>Brief Illness Perception Questionnaire (BIPQ) would be used to assess illness perception.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social support</measure>
    <time_frame>Baseline</time_frame>
    <description>Multidimensional Scale of Perceived Social Support (MSPSS) would be used to assess social supports.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body image</measure>
    <time_frame>Baseline</time_frame>
    <description>Body Image Scale (BIS) would be used to assess body image.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resilience</measure>
    <time_frame>Baseline</time_frame>
    <description>Connor-Davidson Resilience Scale (CDRS) would be used to assess resilience.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal level</measure>
    <time_frame>Week 2</time_frame>
    <description>Serum estradiol, follicle-stimulating hormone (FSH) and anti-Müllerian hormone (AMH) levels would be used to examine pathophysiological mechanisms associated with the presence of hot flashes, mood status and desvenlafaxine treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic polymorphism</measure>
    <time_frame>Week 2</time_frame>
    <description>estrogen receptors (ESR1 PvuII; rs#2234693 and XbaI; rs#9340799 and ESR2-02; rs#4986938) and serotonin transporter gene (SLC6A4; rs#11080121) would be used to examine pathophysiological mechanisms associated with the presence of hot flashes, mood status and desvenlafaxine treatment.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">339</enrollment>
  <condition>Hot Flashes</condition>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Desvenlafaxine succinate 100mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Titration with 50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 2 tablets of 50mg Desvenlafaxine succinate tablet once daily for 3 weeks, then taper with 50 mg Desvenlafaxine succinate tablet once daily for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Desvenlafaxine succinate 50mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 1 tablets of 50mg Desvenlafaxine succinate tablet and 1 tablet of 50mg placebo tablet once daily for 3 weeks, then 50mg placebo tablet once daily for 3 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 mg placebo tablet once daily for 1 week, then 2 tablets of 50mg placebo tablet once daily for 3 weeks, then 50 mg placebo tablet once daily for 3 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine succinate 100mg</intervention_name>
    <description>Pristiq 100mg</description>
    <arm_group_label>Desvenlafaxine succinate 100mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desvenlafaxine succinate 50mg</intervention_name>
    <description>Pristiq 50mg</description>
    <arm_group_label>Desvenlafaxine succinate 50mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        i. Women age 18 years and older with localized breast cancer. Histologic documentation of
        atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ
        (LCIS), or invasive adenocarcinoma of the breast stages I-III A.

        ii. Current daily tamoxifen use (≥ 6 days/week). Any planned surgery, adjuvant chemotherapy
        or radiation must have been completed.

        iii. History of bothersome hot flushes: ≥ 14 hot flushes/week (average ≥ 2 hot
        flushes/day), sufficiently severe that intervention is desired. Participants must have had
        bothersome hot flushes for at least one month prior to enrollment.

        Exclusion Criteria:

        i. Women who is pregnant or breast feeding, or who has a history of seizure disorder or
        hepatic or renal insufficiency ii. Concurrent systemic hormone replacement therapy
        (estrogen, progestational agents, androgens) or use of corticosteroids iii. Concurrent use
        of other antidepressants, anxiolytics and antipsychotics, gabapentin, pregabalin and
        clonidine for treatment of hot flushes or depression.

        iv. Presense or past history of severe psychiatric symptoms such as hallucinations and
        delusions, manic episodes, or high suicide risk.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bong-Jin Hahm, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyung-Lak Son, M.D.</last_name>
    <phone>82-02-2072-3767</phone>
    <email>klson01@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hyun-Jung Lee, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hyun-Jung Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeong-Hyun Kim, M.D., Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Jeong-Hyun Kim, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyung-Lak Son, M.D.</last_name>
      <phone>82-02-2072-3767</phone>
      <email>klson01@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 24, 2016</study_first_submitted>
  <study_first_submitted_qc>June 28, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>April 17, 2018</last_update_submitted>
  <last_update_submitted_qc>April 17, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hot Flashes</keyword>
  <keyword>Breast Neoplasms</keyword>
  <keyword>Tamoxifen</keyword>
  <keyword>Desvenlafaxine Succinate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tamoxifen</mesh_term>
    <mesh_term>Desvenlafaxine Succinate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

